ClinicalTrials.gov
public full text
Public Domain
Oral Cannabidiol for Opioid Withdrawal
This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; all participants will receive placebo dosing and active cannabidiol. Results may be used to support an R01 grant application to more closely examine this hypothesis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults#872305
- Cannabis and Opioid Use Disorder, Study 2#1008539
- Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder#1243147
- Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder#869985
- Development of an Opioid Withdrawal Clinical Outcome Assessment#841650
Record · ID 1295517
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive